YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Key Points Interested in Red Cat Holdings, Inc.? Here are five stocks we like better. Analysts believe Red Cat Holdings, Taysha Gene Therapies, and Solaris Resources could each at least double in value, though all carry elevated risk. Red…
Earnings Call Insights: Taysha Gene Therapies (TSHA) Q2 2026 MANAGEMENT VIEW * "The second quarter of 2026 was a highly productive period for Taysha," said CEO Sean Nolan, highlighting "the completion of dosing in both the REVEAL pivotal a…
Major earnings expected before the bell on Wednesday include: * Nebius Group N.V. (NBIS [https://seekingalpha.com/symbol/NBIS]) * Tencent Holdings Limited (TCEHY [https://seekingalpha.com/symbol/TCEHY]) * Brinker International (EAT [https:…
DALLAS, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogeni…
CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc., (Nasdaq: TSHA) (Taysha), a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene thera…
Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the 10 affordable biotech stocks to buy right now. On June 24, Taysha Gene Therapies Inc. (NASDAQ:TSHA) disclosed the pricing of an underwritten public offering of 32.5 million of its comm…
Nagendran Sukumar, president and head of R&D at Taysha Gene Therapies, Inc. (NASDAQ:TSHA), sold 200,000 shares of common stock on July 10, 2026, for proceeds of $1.2 million, according to a recent SEC Form 4 filing. Transaction summary Met…
Key Points The transaction involved the sale of 200,000 shares at a weighted average price of $6.24 per share on July 10. This disposal reduced the insider's direct common stock holdings by 18%. The activity was executed under a Rule 10b5-…
[Analyzing Business Performance Through Data Analytics] U.S. stock futures edged higher on Thursday, supported by a stellar earnings report from Micron Technology, as markets turned their focus to the release of key May inflation data for…
Taysha Gene Therapies (TSHA [https://seekingalpha.com/symbol/TSHA]) shares slumped 9.2% after-hours on Wednesday after pricing of an underwritten public offering [https://seekingalpha.com/pr/20563312-taysha-gene-therapies-announces-pricing…
(RTTNews) - Taysha Gene Therapies, Inc. (TSHA), a clinical-stage biotechnology company focused on developing gene therapies, priced the offering of 32.50 million shares of its common stock at a price of $6 per share and pre-funded warrants…
DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogeni…
Is TSHA a good stock to buy? We came across a bullish thesis on Taysha Gene Therapies, Inc. on BioEquity Watch's Substack. In this article, we will summarize the bulls' thesis on TSHA. Taysha Gene Therapies, Inc.'s share was trading at $5.…
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the best small cap stocks to buy for 10x potential. Taysha Gene Therapies, Inc. (NASDAQ:TSHA) announced financial results for fiscal Q1 2026 on May 6, reporting that it reaffirmed U.S. Fo…
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the 10 Best US Stocks Under $5 to Buy. On May 6, Canaccord reiterated its Buy rating on Taysha Gene Therapies, Inc. (NASDAQ:TSHA) with a price target of $17 on the stock. This update come…
(RTTNews) - Taysha Gene Therapies Inc. (TSHA), a clinical-stage biotechnology company, said preclinical in vitro data on TSHA-102, a scAAV9 gene therapy developed for treating Rett syndrome will be presented at the annual meeting of the Am…
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock is up 343.45% from its price a year ago and 22.48% year-to-date. On April 15, Needham reiterated its buy rating fo…
Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the best healthcare penny stocks to buy according to hedge funds. On April 6, Canaccord reiterated its Buy rating on Taysha Gene Therapies Inc. (NASDAQ:TSHA) and raised its price target to…
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the best multibagger penny stocks to invest in. On March 25, Cantor Fitzgerald reiterated an Overweight rating on Taysha Gene Therapies (NASDAQ:TSHA) with a $19 price target.Taysha Gene T…
Key Points B Group acquired 90,000 shares of Structure Therapeutics in the fourth quarter. The quarter-end position value increased by $6.26 million due to the new holding. The new stake accounted for 4.62% of the fund’s 13F assets, placin…
On February 17, 2026, B Group, Inc. disclosed a new position in Structure Therapeutics(NASDAQ:GPCR), acquiring 90,000 shares in the fourth quarter. What happened B Group disclosed in a Securities and Exchange Commission (SEC) filing dated…
Earnings Call Insights: Taysha Gene Therapies (TSHA) Q4 2025 MANAGEMENT VIEW * CEO Sean Nolan highlighted 2025 as "a year of significant execution" for Taysha, calling attention to "compelling REVEAL Phase I/II data across pediatric, adole…
Taysha Gene Therapies logo Key Points Regulatory and trial progress: TSHA-102 received FDA Breakthrough Therapy designation, Taysha has initiated the REVEAL pivotal trial and obtained clearance for the safety-focused ASPIRE study, with FDA…
* Taysha Gene Therapies press release [https://seekingalpha.com/pr/20444333-taysha-gene-therapies-reports-full-year-2025-financial-results-and-provides-corporate-update] (TSHA [https://seekingalpha.com/symbol/TSHA]): FY GAAP EPS of -$0.34…
Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate ASPIRE trial in three patients aged 2 to…
* Taysha Gene Therapies (TSHA [https://seekingalpha.com/symbol/TSHA]) is scheduled to announce FY earnings results on Thursday, March 19th, before market open. The consensus EPS Estimate is -$0.34 [https://seekingalpha.com/symbol/TSHA/earn…
DALLAS, March 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogen…
DALLAS, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogeni…
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Taysha Gene Therapies, Inc. is placed sixth on our list of best biotech stocks under $20. TheFly reported on January 5 that Wells Fargo raised its price target…
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the best strong buy stocks to invest in under $5. Needham maintained a bullish outlook on Taysha Gene Therapies, Inc. (NASDAQ:TSHA) on January 6, reiterating a Buy rating on the stock wit…
We came across a bullish thesis on Compass Therapeutics, Inc. on r/stocks by Cute_Confidence6033. In this article, we will summarize the bulls’ thesis on CMPX. Compass Therapeutics, Inc.'s share was trading at $5.70 as of January 16th.Tays…
Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the best penny stocks to buy for 2026. On January 6, the company confirmed that the dosing of the first patient in the REVELA pivotal trial began. The trial is evaluating TSHA-102, a gene…
With strong 1-year returns and upside potential, Taysha Gene Therapies, Inc. (NASDAQ:TSHA) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026.Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Contin…
DALLAS, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogeni…
Taysha Gene Therapies Inc. (NASDAQ:TSHA) is a must-buy penny stock to buy now. On November 13, Piper Sandler analyst Biren Amin reaffirmed his Buy rating on Taysha Gene Therapies, assigning a $9 price target. On November 5, Truist Financia…
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the 12 Best American Penny Stocks to Buy Right Now. On November 5, Citizens increased its price target on Taysha Gene Therapies, Inc. (NASDAQ:TSHA) from $6 to $8 and kept a Market Outperf…